key: cord-0939410-qtr76n96 authors: Senkalfa, Burcu Pınar; Eyuboglu, Tugba Sismanlar; Aslan, Ayse Tana; Gursoy, Tugba Ramaslı; Soysal, Azime Sebnem; Yapar, Dilek; İlhan, Mustafa Necmi title: Effect of the COVID‐19 pandemic on anxiety among children with cystic fibrosis and their mothers date: 2020-06-12 journal: Pediatr Pulmonol DOI: 10.1002/ppul.24900 sha: 523d864943e727529dcce5a2ad0fbc373b76f65f doc_id: 939410 cord_uid: qtr76n96 BACKGROUND: We aimed to evaluate anxiety among children with cystic fibrosis (CF) and their mothers related to the COVID‐19 pandemic. METHODS: A total of 45 patients with CF and their mothers were enrolled in the study together with 90 age‐matched healthy children and their mothers as a control group. The State and Trait Anxiety Inventory (STAI) was administered by teleconference with children aged 13–18 years old and their mothers. The STAI for children was administered with children aged 9–12 years. Results were compared with age‐matched healthy children and their mothers. The relationship between anxiety scores of children with CF and their mothers was evaluated by comparing with clinical data of children with CF. At the conclusion of the teleconference, mothers were asked whether their anxiety had changed as a result of the interview. RESULTS: It was found that healthy children aged 13–18 years had higher state anxiety scores than age‐matched children with CF. Mothers of children with CF had higher trait anxiety scores, especially those of children aged 0–12 years, than mothers of healthy children (p<0.05). For mothers of children with CF, state anxiety scores were higher among those whose children had chronic Pseudomonas infection (p<0.05). Most mothers of children with CF stated that their anxiety decreased following the interview. CONCLUSION: The COVID‐19 pandemic may increase anxiety among mothers of children with CF as well those with healthy children. However, COVID‐19 had no effect on the anxiety of children with CF. Informing parents of children with CF about COVID‐19 by teleconference may decrease anxiety. This article is protected by copyright. All rights reserved. Cystic fibrosis (CF) is a chronic, life-shortening disease with multisystemic involvement. The respiratory system is affected in most patients with CF, with chronic pulmonary infections that lead to respiratory failure being the main cause of death for these patients 1, 2 . Major causes of morbidity and mortality are respiratory complications 3 , and chronic illnesses can cause a number of psychological problems and distress among children and their parents 4-6 . Many studies have shown that depression and anxiety rates are elevated among children with CF and their parents [7] [8] [9] [10] . It has been shown that general family functions, depression, and anxiety symptoms show a strong relationship with health outcomes among patients with CF 11, 12 . Anxiety and depressive symptoms are associated with poorer quality of life, low lung function, reduced physical functioning, and severity of chest symptoms 9 . Parental anxiety and depression increase the risk of depression and anxiety also in the child and negatively affect the treatment compliance and health outcomes 13 . Determination and treatment of parental mental health problems such as depression and anxiety might improve the child's adherence to treatment 14 . Therefore, routine annual screening of depression and anxiety is recommended for patients with CF and their families 15 . The disease first appeared in the Hubei province of China, and whilst it follows human-to-human transmission, the pathway for this virus to establish human infection remains a mystery 16 . Mild fever, dry cough, nasal congestion, sore throat, headache, muscle pain, and malaise are observed among milder patients, with some patients being asymptomatic. Moderate-to-severe patients experience respiratory symptoms such as dyspnea, shortness of breath, and tachypnea, which can result in severe pneumonia and acute respiratory distress syndrome leading to mortality 17 . The mortality risk was found to be increased among patients with underlying diseases, secondary infections, and elevated inflammatory indicators 18 . In the initial stage of COVID-19 infection in China, a cross-sectional study was conducted for evaluating immediate psychological responses and associated factors in general population which indicated that one third of subjects had moderate-to-severe anxiety; moreover, female gender, student status, specific physical symptoms (such as muscle pain, dizziness, and coryza), poor selfreported health status and having a chronic ilness were significantly associated with adverse psychological effect as a result of the outbreak (such as higher levels of stress, anxiety, and depression) 19 . Another cross-sectional study in 7143 college students demonstrated that 21.3% had mild and 3.6% had moderate-to-severe anxiety symptoms where economic effects on daily life and delays in academic activities were positively associated with anxiety symptoms 20 . Viral respiratory infections take a more severe course among patients with CF than among the general population and negatively affect lung function. During the 2009 influenza pandemic, the H1N1 virus caused significant morbidity among patients with CF, and in a subgroup with severe lung disease, H1N1 infection was associated with respiratory impairment, mechanical ventilation, and even death 21,22 . This article is protected by copyright. All rights reserved. Therefore, there is a strong probability that COVID-19 may cause anxiety among children with CF and their families. We aimed to evaluate anxiety experienced by children with CF and their mothers following COVID-19 being declared a global pandemic by the World Health Organization (WHO). We also aimed to compare the results to age-matched healthy children and their mothers about how intensity of anxiety elevations may differ between the two groups. And to compare the anxiety levels of children and mothers according to the children's gender and age groups. As clinical severity of CF may affect the anxiety status of patients and their parents we investigated the relation between the anxieties of both the children and their mothers and clinical findings of children with CF. Another aim of this study was the evaluation of the effect of the provided information about COVID-19 by their own doctors to parents of children with CF. The study included all children aged 0-18 years with CF and their mothers who were patients at the pediatric pulmonology department. Totally 48 patients who have been followed regularly in pediatric pulmonology department were called by phone. Two patients could not be reached and one patient declined to participate in the study. A total of 45 patients with CF and their mothers were included in the study group and 90 healthy age-matched children and their mothers were placed in a control group. Healthy children did not come to hospitals except emergency situations because of transmission risk of COVID-19 during the study period. Children in control group were recruited through snowball sampling. Children of medical system workers were not included the study due to the fact that they might have more knowledge and higher anxiety about COVID-19 because of the high risk of viral This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. Mean follow-up duration which was defined as the time period between the time of the diagnosis of CF and the last control time in the clinic was noted. Results for pulmonary function tests (PFT) were recorded for patients who could perform in the last control, and forced vital capacity (FVC), forced expiratory volume (FEV), FEV in 1 s (FEV1), and forced expiratory flow (FEF25-75) spirometry tests were recorded as predicted percentages. In addition, the FEV1/FVC ratio was recorded and assessed based on age, gender, and height, and the modified Shwachman-Kulczycki Score (mSKS) was used to determine the clinical severity of the disease. Scores were provided for four sections: general activity, findings from physical examination, nutritional status, and radiological findings. Each parameter was scored from 5 (severely impaired) to 25 (normal), which resulted in a total score categorized as excellent (86-100), good (71-85), mild (56-70), moderate (41-55), and severe (<40) 26, 27 . Clinical severity of CF was rated by the same pediatric pulmonologist. Scales related to anxiety were applied by teleconference with children aged over 9 years with CF and their mothers. Patients with CF and their mothers were identified as the 'study group'. A 'control group' consisted of age-matched healthy children and their mothers who had also been enrolled in the study. Anxiety scales were applied by teleconference to children older than nine years, and all mothers. Anxiety scales were not applied to participants younger than nine years of age. The State-Trait Anxiety Inventory for Children (STAI-C) is an anxiety measurement tool for evaluating the state and traits of anxiety among children aged 9-12 years. It contains two separate scales to measure the concepts of state and trait anxiety. The state scale, which is a measure of temporary anxiety states, consists of 20 items asking children how they feel at the present time. The trait scale consists of 20 items that ask This article is protected by copyright. All rights reserved. Accepted Article children how they feel in general. This measures relatively stable individual differences in anxiety trends. Items are rated on a 3-point scale with responses: hardly ever, sometimes, and often [28] [29] [30] . Higher scores indicate a higher level of anxiety. Validation and reliability study of the Turkish version was performed by Özusta 30 . For children aged 13-18 years (and all mothers), the State-Trait Anxiety Inventory (STAI) was used. This is used to measure the presence and severity of existing anxiety symptoms and general anxiety tendencies. The test-retest reliability coefficients in the initial development ranged from 0.31 to 0.86 with intervals ranging from 1 hour to 104 days 31 . Validation and reliability study of the Turkish version was performed by Oner and Le Compte 32 . There are two sub-scales within this scale. First, the state-anxiety inventory (consisting of 20 items) evaluates the current state of anxiety and asks how participants feel "right now" using items that measure subjective anxiety, tension, nervousness, anxiety, and activation/arousal. The responses of the state-anxiety scale evaluate the "present" intensity of current emotions: 1) not at all, 2) somewhat, 3) moderately so, and 4) very much so. The traitanxiety scale (also consisting of 20 items) evaluates relatively stable aspects of "anxiety tendency," including general calmness, trust, and security situations. The responses of the trait-anxiety scale evaluate the "in general" frequency of emotions: 1) almost never, 2) sometimes, 3) often, and 4) almost always 31, 32 . Higher scores indicate a higher level of anxiety. Since the COVID-19 pandemic is a newly emerging situation, the current anxiety of children was measured using the STAI and STAI-C state scales and general anxiety was measured using the trait scale of STAI and STAI-C. At the end of the teleconference, after informing the mothers about COVID-19 they were asked whether their anxiety had changed as a result of the interview. Answers were noted as decreased, increased, or not changed. All data collected from mothers and children were compared between the study and control groups. In the study group, the relation between anxiety results of All mothers were primary caregivers for their children. Table 2 . Neither state not trait anxiety scores differed by gender for 9-12 year olds and 13-18 year olds in both study and control groups (p > 0.05). Anxiety scores for children according to age group were compared between the study and control groups. It was found that state anxiety scores for children aged 13-18 years in the control group were higher than for the age- Table 3 . When the results for mothers' anxiety were evaluated, trait anxiety in the study group was significantly higher than in the control group ( 41.7 ± 8.9 vs 36. However, there were no significant differences between mothers in the study and control groups when comparing state and trait anxiety scores according to the children's age groups (p > 0.05). Comparisons of anxiety status between mothers in both groups and according to their children's age are shown in Table 4 . There was no significant correlation between mother's state and trait anxiety Mothers' anxiety in the study group decreased significantly compared with mothers in the control group (p = 0.000). The burden and effects of COVID-19 are felt all around the world, and this is likely to cause fear and anxiety. In our study, trait anxiety for mothers of children with CF was found to be especially high for those with younger children; however, children with CF had no elevated anxiety scores compared with healthy children in the control group. It was also found that the teleconference with mothers of children with CF made them feel less anxious about the COVID-19 pandemic. Many studies have shown that patients with CF have higher levels of anxiety compared with healthy controls 33, 34 . Anxiety symptoms were found to be more frequent among the adolescent population and adults compared with the general population, with a prevalence of 11%-33% 9 . Among patients with CF in the 7-14 year-age group, anxiety was reported as the most prevalent diagnosis 35 . However, in our study, healthy children aged 13-18 years had higher state anxiety scores, and girls demonstrated higher anxiety levels than boys. Similar to the findings of a study on children and adolescents with non-CF bronchiectasis, state anxiety was found to be higher in the healthy control group 36 . Since children with CF experience constant disease anxiety, their scores may be increased during the COVID-19 pandemic. However, more pronounced anxiety among healthy children may be because these children have not encountered the fear of disease before. Facing the risk of experiencing a serious health problem for the first time may increase their fear and anxiety. Perhaps CF could be protective in some way as these children have already This article is protected by copyright. All rights reserved. Elevated rates of anxiety symptoms have been found to be negatively correlated with quality of life among parents of children with CF, notably elevated levels of depressive symptoms 10, 37 . These are all known to affect the health outcomes of children with CF. In our study, mothers of children with CF aged 0-12 years had higher trait anxiety scores than mothers of healthy children in the same age group. However, there were no differences among mothers of children aged 13-18 years. Mean mSKS and PFT results were higher among our patients with CF, which may help them to feel good in terms of their disease. In a study with adolescent children with CF, caregivers' anxiety scores were associated with adolescents' scores, and lower anxiety symptoms were found among adolescent patients who had adapted quite well to their illness 38 . These could be compatible with our results. In our study there was a moderate, positive correlation between the state anxiety scores of the mothers and trait anxiety scores of the 9-12 year-old children. Compatible with our results, it was demonstrated that elevated anxiety levels of mothers lead to an increase which is also more likely to be elevated among teens 15 . Pseudomonas aeruginosa is associated with an increased rate of decline in FEV1, a failure to recover baseline lung function after a pulmonary exacerbation, and This article is protected by copyright. All rights reserved. shortened survival 39 . Chronic Pseudomonas infection was found to be related with anxiety among patients with bronchiectasis unrelated to CF 40, 41 . Furthermore, Pseudomonas aeruginosa infection was shown to be significantly associated with higher caregiver burden 41 . There is evidence that parents of children with CF may be very anxious about the acquisition of Pseudomonas aeruginosa 42, 43 Cystic fibrosis: a clinical view Acute pulmonary and non-pulmonary complications in adults with cystic fibrosis Cystic fibrosis Psychological functioning of adults with cystic fibrosis Depressive symptoms in children and adolescents with chronic physical illness: an updated meta-analysis Predictors of depressive symptoms in parents of chronically ill children admitted to the pediatric intensive care unit Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries Screening for depression in a single CF centre Relationship between anxiety, depression, and quality of life in adult patients with cystic fibrosis Anxiety, depression, and life satisfaction in parents caring for children with cystic fibrosis Family correlates of a 10-year pulmonary health trend in cystic fibrosis The impact of family functioning on health changes in children with cystic fibrosis Maintaining Mental Health and Function for the Long Run in Cystic Fibrosis Parental Depression and Pancreatic Enzyme Adherence in Children with Cystic Fibrosis The psychological burden of cystic fibrosis The Coronavirus Pandemic: What Does the Evidence Show? COVID-19): A Review of Clinical Features, Diagnosis, and Treatment Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China The psychological impact of the COVID-19 epidemic on college students in China Impact of COVID-19 on people with cystic fibrosis Kerem E; ECFS (A) H1N1 study group. Impact of the A (H1N1) pandemic influenza (season 2009-2010) on patients with cystic fibrosis WHO. Coronavirus disease (COVID-19) advice for the public WHO. Coronavirus disease (COVID-19) advice for the public: Myth busters Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients Long-term study of 105 patients with cystic fibrosis Shwachman Score in Clinical Evaluation of Cystic Fibrosis Hospitalized Children: Anxiety, Coping Strategies, and Pretend Play State-Trait Anxiety Inventory for Children -STAIC: Professional manual Çocuklar için durumluk sürekli kaygı envanteri uyarlama geçerlik ve güvenilirlik çalışması Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Prevalence of symptoms of anxiety and depression in German patients with cystic fibrosis Anxiety and depression in cystic fibrosis A matched comparison of adjustment in children with cystic fibrosis and psychiatrically referred and nonreferred children The relationship between psychological symptoms, lung function and quality of life in children and adolescents with noncystic fibrosis bronchiectasis Relations between depressive and anxious symptoms and quality of life in caregivers of children with cystic fibrosis Anxiety and depression in adolescents with CF and their caregivers Cystic Fibrosis Lung Disease: An Overview Presence of anxiety and depression in patients with bronchiectasis unrelated to cystic fibrosis Pseudomonas aeruginosa isolation in patients with non-cystic fibrosis bronchiectasis: a retrospective study Parental fears of Pseudomonas infection and measures to prevent its acquisition Perception of first respiratory infection with Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online qualitative study